2023. Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. SKIN The Journal of Cutaneous Medicine. 7, 4 (Jul. 2023), s218. DOI:https://doi.org/10.25251/skin.7.supp.218.